Noile-Immune Biotech Inc. AI Stock Analysis
Want to see JP:4893 full AI Analyst Report?
Noile-Immune Biotech Inc. (4893) AI Stock Analysis
Noile-Immune Biotech Inc.
(TSE/TYO:4893)
The overall score of 41 is heavily weighed down by a severe top-line revenue collapse, deeply negative earnings, and a strong technical downtrend. While the zero-debt balance sheet provides temporary operational runway, the total lack of profitability and persistent cash burn are primary risk factors driving this low score.
Noile-Immune Biotech Inc. (4893) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.78B
- Dividend Yield
- ―
- Average Volume (3M)
- 208.69K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- 0.89
- Revenue Growth
- -92.30%
- EPS Growth
- -8.80%
- Country
- Japan
- Employees
- 23
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Noile-Immune Biotech Inc. Business Overview & Revenue Model
Company Description
Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.
Noile-Immune Biotech Inc. Financial Statement Overview
Summary
Despite a pristine balance sheet with zero debt, financial performance is severely constrained by collapsing revenue, persistent cash burn, and deep net losses typical of early-stage biotechs without commercial scale.
Income Statement
10Very NegativeBalance Sheet
85Very PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 715.00K | 5.00M | 7.59M | 316.82M | 625.78M | 100.73M |
| Gross Profit | 0 | 5.00M | 7.39M | 314.56M | 618.71M | 77.83M |
| EBITDA | -800.73M | -797.25M | -1.07B | -775.39M | -106.34M | -767.51M |
| Net Income | -753.88M | -793.54M | -964.46M | -1.13B | -386.62M | -795.03M |
Balance Sheet | ||||||
| Total Assets | 3.66B | 4.01B | 4.80B | 5.78B | 4.64B | 4.27B |
| Cash, Cash Equivalents and Short-Term Investments | 3.54B | 3.92B | 4.67B | 5.56B | 4.52B | 4.14B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 90.34M | 79.64M | 74.67M | 91.49M | 340.42M | 85.72M |
| Stockholders Equity | 3.57B | 3.93B | 4.73B | 5.69B | 4.30B | 4.19B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | -887.81M | -873.08M | -107.18M | -777.14M |
| Operating Cash Flow | 0 | -752.22M | -887.81M | -873.08M | -107.18M | -777.14M |
| Investing Cash Flow | 0 | -378.00K | 557.00K | -5.32M | 0 | -4.03M |
| Financing Cash Flow | 0 | -20.00K | 2.50M | 1.91B | 487.62M | 2.37B |
Noile-Immune Biotech Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4893, the sentiment is Negative. The current price of 87.00 is above the 20-day moving average (MA) of 86.75, below the 50-day MA of 110.84, and below the 200-day MA of 135.18, indicating a neutral trend. The MACD of -6.61 indicates Negative momentum. The RSI at 37.18 is Neutral, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4893.
Noile-Immune Biotech Inc. Peers Comparison
Overall Rating
JP:488049Neutral
JP:375045Neutral
JP:456441Neutral- JP:489341Neutral
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4880 | 49Neutral | JPY 5.58B | 56.74 | ― | 1.78% | -9.94% | ― |
| JP:3750 | 45Neutral | JPY 6.94B | -12.75 | ― | ― | 15.47% | 69.34% |
| JP:4564 | 41Neutral | JPY 6.94B | -6.96 | -42.81% | ― | -25.56% | 17.01% |
| JP:4893 | 41Neutral | JPY 3.85B | -5.00 | ― | ― | -92.30% | -8.80% |
| JP:7776 | 39Underperform | JPY 6.70B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4599 | 38Underperform | JPY 7.46B | -3.94 | ― | ― | ― | 4.85% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4893 | Noile-Immune Biotech Inc. | 87.00 | -68.00 | -43.87% | |
| JP:4564 | OncoTherapy Science, Inc. | 16.00 | -7.00 | -30.43% | |
| JP:3750 | Cytori Cell Research Institute, Inc. | 800.00 | -32.00 | -3.85% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4880 | CellSource Co., Ltd. | 282.00 | -215.00 | -43.26% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026